



UNITED STATES DEPARTMENT OF COMMERCE **Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

	APPLICATION NO. FILING DATE		FIRST NAMED INVENTOR			A	ITORNEY DOCKET NO.
	U87439, U9!	5 05/11/9	3 MATSUI			1	40379/119
Γ	FOLEY & LARDNER SUITE 500		18M2/1	208 -	٦	EXAMINER MARSCHEL, A	
	3000 K STI WASHINGTO	REET NW N DC 20007-	5109			ART UNIT	PAPER NUMBER
						DATE MAILED:	12/08/97

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

	Application No. Applicant(s) 08/439.095 Matain et al.						
Office Action Summary	Examiner Ardin Manschel 1809						
\bowtie Responsive to communication(s) filed on $8/25$	<i>1</i> 97						
M This action is FINAL.							
Since this application is in condition for allowance exists accordance with the practice under Ex parte Quay!	cept for formal matters, prosecution as to the merits is closed e, 1935 C.D. 11; 453 O.G. 213.						
A shortened statutory period for response to this action	is set to expire month(s), or thirty days, whichever Failure to respond within the period for response will cause the Extensions of time may be obtained under the provisions of						
Disposition of Claims	21						
	— 36 is/are pending in the application.						
01 the above; (laim(s) 1-3,7-21, 23	3, and 24 have we total wither own from consideration.						
Ø Claim(s) 22 and 26-33	is/are pending in the application. 3, and 24 have been canceled. is/are allowed. is/are rejected.						
A Claim(s) 4-6, 25, and 34-3	is/are rejected.						
	is/are objected to.						
	are subject to restriction or election requirement.						
 ☐ The drawing(s) filed on is/are objected to by the Examiner. ☐ The proposed drawing correction, filed on is ☐ approved ☐ disapproved. ☐ The specification is objected to by the Examiner. 							
☐ The oath or declaration is objected to by the Exam	niner.						
Priority under 35 U.S.C. § 119 Acknowledgement is made of a claim for foreign All Some* None of the CERTIFIED received. received in Application No. (Series Code/S received in this national stage application *Certified copies not received: Acknowledgement is made of a claim for domes	erial Number) from the International Bureau (PCT Rule 17.2(a)).						
Attachment(s) Notice of References Cited, PTO-892 Information Disclosure Statement(s), PTO-1449, Interview Summary, PTO-413 Notice of Draftsperson's Patent Drawing Review							
□ Notice of Informal Patent Application, PTO-152							
SEE OFFICE ACT	TION ON THE FOLLOWING PAGES						

Applicants' arguments, filed 8/25/97, have been fully considered but they are not deemed to be persuasive. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are newly applied. They constitute the complete set presently being applied to the instant application.

The title of the invention is not descriptive. A new title is required that is clearly indicative of the invention to which the claims are directed. The present title only cites a gene whereas in contrast both nucleic acids and proteins are claimed.

Claims 4-6 and 25 are rejected, as discussed below, under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 4-6 and 25 depend either directly or indirectly from claim 23 which is a canceled claim and are therefore unclear due to this dependence. It is noted that applicants argued that claim 25 depends from claim 26. This claim 26 dependence, however, has not been amended into claim 25. This rejection is necessitated by amendment.

The following is a quotation of 35 U.S.C. § 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject

- 3 -

matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Subject matter developed by another person, which qualifies as prior art only under subsection (f) or (g) of section 102 of this title, shall not preclude patentability under this section where the subject matter and the claimed invention were, at the time the invention was made, owned by the same person or subject to an obligation of assignment to the same person.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. § 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 C.F.R. § 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. § 102(f) or (g) prior art under 35 U.S.C. § 103(a).

Claims 34-36 are rejected under 35 U.S.C. § 102(b) as anticipated by or, in the alternative, under 35 U.S.C. § 103(a) as obvious over either Hart et al. or Betsholtz et al., taken in view of Raines et al. and further in view of Hart (P/N 5,094,941).

This rejection is necessitated by amendment which effectively replaced instant claim 7 with presently pending claims 34-36. The basis for this rejection is summarized at length in the previous office action, mailed 2/25/97, and herein applied to instant claims 34-36 because applicants still have the burden of appropriately showing distinctness of the present

claims over the reference disclosures. It appears that the same situation exists for presently pending claims 34-36 that existed for the previous claim 7 regarding the instant further characterization of proteins that appear to be identical or obvious given the cited references which contain merely less characterization compared to the instant disclosure. The burden of showing distinctness is shifted to applicants in this situation as supported by the following paragraph that summarizes two legal decisions that are directed to this type of situation.

It is noted that In re Best (195 USPQ 430) and In re Fitzgerald (205 USPQ 594) discuss the support of rejections wherein the prior art discloses subject matter for which there is reason to believe inherently includes functions that are newly cited or is identical to a product instantly claimed. In such a situation the burden is shifted to the applicants to "prove that subject matter shown to be in the prior art does not possess characteristic relied on" (205 USPQ 594, second column, first full paragraph).

Claims 22 and 26-29 are allowed.

Applicants' amendment necessitated the new grounds of rejection. Accordingly, THIS ACTION IS MADE FINAL. See M.P.E.P. § 706.07(a). Applicants are reminded of the extension of time policy as set forth in 37 C.F.R. § 1.136(a).

A SHORTENED STATUTORY PERIOD FOR RESPONSE TO THIS FINAL ACTION IS SET TO EXPIRE THREE MONTHS FROM THE DATE OF THIS

ACTION. IN THE EVENT A FIRST RESPONSE IS FILED WITHIN TWO MONTHS OF THE MAILING DATE OF THIS FINAL ACTION AND THE ADVISORY ACTION IS NOT MAILED UNTIL AFTER THE END OF THE THREE-MONTH SHORTENED STATUTORY PERIOD, THEN THE SHORTENED STATUTORY PERIOD WILL EXPIRE ON THE DATE THE ADVISORY ACTION IS MAILED, AND ANY EXTENSION FEE PURSUANT TO 37 C.F.R. § 1.136(a) WILL BE CALCULATED FROM THE MAILING DATE OF THE ADVISORY ACTION. IN NO EVENT WILL THE STATUTORY PERIOD FOR RESPONSE EXPIRE LATER THAN SIX MONTHS FROM THE DATE OF THIS FINAL ACTION.

This application is subject to the provisions of Public Law 103-465, effective June 8, 1995. Accordingly, since this application has been pending for at least two years as of June 8, 1995, taking into account any reference to an earlier filed application under 35 U.S.C. 120, 121 or 365(c), applicant, under 37 CFR 1.129(a), is entitled to have a first submission entered and considered on the merits if, prior to abandonment, the submission and the fee set forth in 37 CFR 1.17(r) are filed prior to the filing of an appeal brief under 37 CFR 1.192. Upon the timely filing of a first submission and the appropriate fee for a large entity under 37 CFR 1.17(r), the finality of the previous Office action will be withdrawn. In view of 35 U.S.C. 132, no amendment considered as a result of payment of the fee set forth in 37 CFR 1.17(r) may introduce new matter into the disclosure of the application.

If applicant has filed multiple proposed amendments which, when entered, would conflict with one another, specific instructions for entry or non-entry of each such amendment should be provided upon payment of any fee under 37 CFR 1.17(r).

Art Unit: 1809 - 6 - Serial No. 08/439,095 Papers related to this application may be submitted to Group 1800 by facsimile transmission. Papers should be faxed to Group 1800 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notices published in the Official Gazette, 1096 OG 30 (November 15, 1988), 1156 OG 61 (November 16, 1993), and 1157 OG 94 (December 28, 1993) (See 37 CFR § 1.6(d)). The CM1 Fax Center number is (703) 305-3014. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ardin Marschel, Ph.D., whose telephone number is (703) 308-3894. The examiner can normally be reached on Monday-Friday from 8 A.M. to 4 P.M. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, W. Gary Jones, can be reached on (703) 308-1152. Any inquiry of a general nature or relating to the status of this application should be directed to the Chemical Matrix receptionist whose telephone number is (703) 308-0196. December 8, 1997 PRIMARY EXAMINER **GROUP 1800**